Targeted inhibition of @entity421 growth by bone marrow-derived mesenchymal stem cells expressing cytosine deaminase/5-fluorocytosine in @entity5 -bearing XXXX .

@entity1 @entity137 @entity5 @entity19 @entity1050 @entity1759 @entity5399 @entity421
BACKGROUND: Mesenchymal stem cells (MSCs) are considered an attractive approach for gene or drug delivery in @entity5 therapy. Thus, in this study, the ability of @entity1 bone marrow-derived MSCs expressing the cytosine deaminase/5-fluorocytosine prodrug ( @entity1050 /5-FC MSCs) to target the @entity1 @entity421 cell line Cal72 was evaluated. METHODS: The stable @entity1050 /5FC MSC cell line was established by transfection of pEGFP containing the cytosine deaminase gene into MSCs with G418 selection. The anti- @entity5 effect was verified by a bystander effect assay in vitro and co-injection of Cal72 and @entity1050 /5FC MSCs in @entity5 -bearing @entity19 . RESULTS: The therapeutic @entity1050 /5-FC MSCs retained the characteristics of multipotent cells such as differentiation into adipocytes/osteocytes and expression of mesenchymal markers ( @entity5399 and @entity1759 ), and showed migration toward @entity1 cells to a greater extent than the native MSCs. The bystander effect assay showed that the @entity1050 /5-FC MSCs significantly augmented Cal72 @entity137 in direct co-culture and in the presence of 5-FC through the application of conditioned medium. In @entity421 -bearing @entity19 , the @entity1050 /5-FC MSCs inhibited @entity5 growth when compared with control @entity19 subcutaneously injected with only @entity1 cells. CONCLUSIONS: Taken together, these findings suggest that @entity1050 /5-FC MSCs may be suitable for targeting @entity1 @entity421 . This article is protected by copyright. All rights reserved.
